In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Newron Pharmaceuticals SpA, with a price target of CHF26.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Ram Selvaraju has given his Buy rating due to a combination of factors including the initiation of the ENIGMA-TRS 2 Phase 3 clinical trial in the U.S., which marks a significant advancement in Newron Pharmaceuticals’ late-stage clinical program for evenamide. The trial’s design, which includes well-validated outcome measures and a diverse patient enrollment, positions evenamide for a broad label in treating schizophrenia.
The ENIGMA-TRS 2 study is a global, randomized, double-blind, placebo-controlled trial that evaluates evenamide as an add-on therapy for treatment-resistant schizophrenia (TRS). The study’s comprehensive approach, including a 42-day screening period and oversight by an Independent Eligibility Assessment Committee, underscores the robustness of the trial. These strategic developments and the potential for regulatory submission by mid-2027 support Selvaraju’s optimistic outlook and the reiteration of a Buy rating with a 12-month price target of CHF26.
In another report released on December 2, TR | OpenAI – 4o also reiterated a Buy rating on the stock with a CHF22.00 price target.